Ocular Therapeutix Inc. (OCUL) delivered what should have been a celebration moment on Tuesday: their experimental eye drug Axpaxli beat the competition in a head-to-head Phase 3 trial. The problem? Investors were expecting a knockout, and what they got was a solid win on points.

Shares tumbled more than 25% in premarket trading despite the company announcing positive results from its landmark SOL-1 Phase 3 superiority trial in wet age-related macular degeneration, a progressive eye disorder that can lead to vision loss.

According to STAT News, the issue wasn't that Axpaxli failed. It's that the durability advantage over the active control was smaller than Wall Street had hoped for, raising questions about how well it can compete in a market already crowded with effective treatments.

What the Data Actually Showed

The SOL-1 trial compared a single dose of Axpaxli (0.45 mg) against a single dose of Regeneron Pharmaceuticals Inc.'s (REGN) Eylea (aflibercept 2 mg) after an initial loading phase.

Here's where Axpaxli actually performed well: 74.1% of patients treated with the drug maintained their vision at Week 36, compared to 65.9% in the Eylea group. That's a risk difference of 17.5% with strong statistical significance (p=0.0006). By any reasonable measure, that's a meaningful result.

The drug also hit key secondary endpoints and prespecified exploratory measures, either achieving statistical significance or numerical superiority over Eylea. Notably, 80.6% of Axpaxli patients were rescue-free at Week 24, significantly outperforming the comparison group.

The durability question, which seems to be what spooked investors, came at Week 52. Axpaxli maintained vision in 65.9% of subjects compared to 44.2% for Eylea, marking a risk difference of 21.1% with high statistical significance. On paper, that looks impressive. But expectations had apparently run ahead of reality.

Interestingly, Sanofi SA (SNY) was reportedly bidding for Ocular Therapeutix recently, adding another layer to the story about the company's perceived value.

What Comes Next

Ocular Therapeutix plans to submit a New Drug Application based on the SOL-1 data, subject to formal discussions with the FDA. If regulators give the green light, Axpaxli could become the first tyrosine kinase inhibitor commercialized for wet AMD, and potentially the only therapy with both a superiority label and best-in-disease durability claims.

The company is also continuing its complementary SOL-R Phase 3 non-inferiority trial, with topline data expected in the first quarter of 2027.

Market Reaction and Technical Picture

The stock was trading 26.46% lower in premarket action, a sharp reversal from what's been a generally positive longer-term trajectory. Over the past 12 months, shares had climbed 23.33%, though the 52-week range of $5.79 to $16.44 shows the stock has experienced considerable volatility.

With the current decline, shares are positioned closer to the lower end of that range. Technical indicators like RSI and MACD weren't providing clear signals, suggesting traders should approach with caution given the uncertainty around near-term price direction.

Analyst Sentiment

Despite Tuesday's selloff, analysts maintain a Buy rating on the stock with an average price target of $21.00. Recent actions include:

• Chardan Capital: Buy rating, $21.00 target (Dec. 9, 2025)
• Needham: Buy rating, $20.00 target (Dec. 8, 2025)
• HC Wainwright & Co.: Buy rating, raised target to $21.00 (Dec. 8, 2025)

OCUL Price Action: Ocular Therapeutix shares were down 25.45% at $6.62 during Tuesday's premarket session.

The disconnect between the clinical data and the market reaction illustrates a familiar dynamic in biotech investing: sometimes winning isn't enough if expectations have gotten ahead of reality. Axpaxli beat its comparator with statistical significance across multiple measures, but in a competitive market for wet AMD treatments, investors were apparently hoping for something more dramatic.